Form 4: Repare Therapeutics Director Sells Shares in Acquisition

Repare Therapeutics director Ann D. Rhoads reported the disposition of 4,000 common shares as part of an acquisition by XenoTherapeutics, Inc. for $2.20 cash and one CVR per share.

Summary

• Director Ann D. Rhoads disposed of 4,000 common shares of Repare Therapeutics Inc. on January 28, 2026.
• This transaction is a direct result of an Arrangement Agreement dated November 14, 2025.
• Under the agreement, Xeno Acquisition Corp. (the "Purchaser") acquired all outstanding common shares of Repare Therapeutics Inc.
• Shareholders received $2.20 in cash per share and one non-transferable contingent value right (CVR) per share.
• Following this transaction, Ann D. Rhoads beneficially owns 0 common shares directly.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. While the company is being acquired, providing an exit, the cash price is relatively low, offset by the potential upside of the CVR. It's an expected event following a merger agreement.

Positives

• The acquisition provides a clear exit strategy for Repare Therapeutics Inc. shareholders, offering a cash component and potential future value through CVRs.

Negatives

• Repare Therapeutics Inc. will cease to be a publicly traded entity, as all common shares are being acquired.
• The cash consideration of $2.20 per share might be below some investors' expectations, depending on the company's prior valuation and market sentiment.

Risks

• The value of the contingent value right (CVR) is uncertain and depends on future events or milestones, introducing speculative risk for shareholders.
• Shareholders lose direct equity ownership and future upside potential in Repare Therapeutics Inc. as an independent entity.

Future Outlook

The future outlook for Repare Therapeutics Inc. as an independent public entity is its dissolution, as it is being acquired. The future value for shareholders will depend on the performance and realization of the contingent value rights (CVRs).

Industry Context

This transaction represents a consolidation event within the biotechnology or pharmaceutical sector, where smaller companies are often acquired by larger entities for their pipeline, technology, or market position. The use of contingent value rights (CVRs) is a common mechanism in biotech acquisitions to bridge valuation gaps and share future development risks and rewards.

Comparison to Industry Standards

• The inclusion of a contingent value right (CVR) in an acquisition is a standard practice in the biotechnology and pharmaceutical industries, similar to deals such as the acquisition of Acceleron Pharma by Merck or The Medicines Company by Novartis, where CVRs were used to provide additional consideration tied to specific clinical or regulatory milestones.
• The cash component of $2.20 per share would need to be evaluated against recent comparable biotech acquisitions on a per-share or enterprise value basis, considering the stage of Repare's pipeline and market conditions at the time of the Arrangement Agreement.

Stakeholder Impact

• Shareholders: Will receive $2.20 cash per share and one CVR per share, losing direct equity in Repare Therapeutics Inc.
• Employees: Future employment status and benefits will likely be determined by the acquiring entity, XenoTherapeutics, Inc.
• Company (Repare Therapeutics Inc.): Will cease to exist as an independent public entity, becoming part of XenoTherapeutics, Inc.

Next Steps

• Shareholders will receive the cash consideration and CVRs as per the Arrangement Agreement.
• The CVRs will mature based on specific milestones or events outlined in the Arrangement Agreement.

Key Dates

Recommendation

For existing shareholders, the terms of the acquisition (cash plus CVR) are already established, making the transaction largely a mechanical event. For new investors, there is no longer an opportunity to invest in Repare Therapeutics Inc. as a standalone public company. The CVR introduces a speculative element, making it a 'hold' for those who will receive it, as its future value is uncertain.

Keywords

Repare Therapeutics, RPTX, XenoTherapeutics, Acquisition, Merger, Form 4, Insider Transaction, Contingent Value Right, CVR, Director Disposition